| __timestamp | Bristol-Myers Squibb Company | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 4534000000 | 13762000000 |
| Thursday, January 1, 2015 | 5920000000 | 13608000000 |
| Friday, January 1, 2016 | 4940000000 | 14563000000 |
| Sunday, January 1, 2017 | 6411000000 | 14014000000 |
| Monday, January 1, 2018 | 6345000000 | 14805000000 |
| Tuesday, January 1, 2019 | 6148000000 | 14220000000 |
| Wednesday, January 1, 2020 | 11143000000 | 15462000000 |
| Friday, January 1, 2021 | 10195000000 | 17772000000 |
| Saturday, January 1, 2022 | 9509000000 | 24047000000 |
| Sunday, January 1, 2023 | 9299000000 | 32443000000 |
| Monday, January 1, 2024 | 11159000000 | 48062000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, research and development (R&D) are pivotal for innovation and growth. Over the past decade, Novo Nordisk A/S and Bristol-Myers Squibb Company have demonstrated contrasting R&D investment strategies. From 2014 to 2023, Novo Nordisk's R&D expenses surged by approximately 136%, reflecting its commitment to pioneering diabetes and obesity treatments. In contrast, Bristol-Myers Squibb's R&D spending increased by about 105%, underscoring its focus on oncology and immunology advancements.
By 2023, Novo Nordisk's R&D expenses were nearly 3.5 times higher than in 2014, while Bristol-Myers Squibb's expenses doubled. This divergence highlights Novo Nordisk's aggressive investment in innovation, positioning it as a leader in its field. As these pharmaceutical giants continue to invest in R&D, their strategic choices will shape the future of healthcare, offering new hope for patients worldwide.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and Johnson & Johnson
Novo Nordisk A/S vs Genmab A/S: Strategic Focus on R&D Spending
R&D Insights: How Novo Nordisk A/S and United Therapeutics Corporation Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Novo Nordisk A/S and BioMarin Pharmaceutical Inc.
R&D Insights: How Novo Nordisk A/S and ADMA Biologics, Inc. Allocate Funds
Novo Nordisk A/S or Amneal Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Arrowhead Pharmaceuticals, Inc.
R&D Insights: How Novo Nordisk A/S and Taro Pharmaceutical Industries Ltd. Allocate Funds
Comparing Innovation Spending: AstraZeneca PLC and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company vs Takeda Pharmaceutical Company Limited: Strategic Focus on R&D Spending
R&D Insights: How Bristol-Myers Squibb Company and Verona Pharma plc Allocate Funds
Bristol-Myers Squibb Company or Celldex Therapeutics, Inc.: Who Invests More in Innovation?